Biogen Inc.
Biogen Expects $46 Million Expense Impact on Q2 2025 Earnings
Summary
Biogen Inc. anticipates that its GAAP and non-GAAP results for the second quarter of 2025 will be impacted by approximately $46 million in acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce net income per diluted share by approximately ($0.26). The company began presenting these expenses as a separate line item in its condensed consolidated statements of income in the first quarter of 2025. The final results for the quarter ended June 30, 2025, are subject to financial statement closing procedures and may differ from the preliminary estimates provided.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement